“Breakthrough” Means Breaking Down Bureaucracy
This article was originally published in RPM Report
Executive Summary
FDA’s Richard Pazdur has the oncology review team at FDA out on the cutting edge of “Breakthrough” reviews. He sees the key elements of making breakthrough work as cutting through layers of traditional processes and setting faster pathways for subsequent drugs.
You may also be interested in...
CDER Office of Product Quality Ready To Go: New Structure Sends Strong Signal To Industry
It took a while, but the Office of Pharmaceutical Quality is finally ready to begin operations. Biopharma companies should recognize the declaration of FDA’s priorities, and respond accordingly.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.
As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate
Positive tandem ICER reviews for bluebird bio’s and Vertex/CRISPR’s gene therapies show the impact that concerns about addressing racial inequities could create a favorable context for products as they enter pricing and coverage discussions.